Abstract
<div class="authors authors-lg"><div class="author"><div class="author-img"><img src="https://cdn.insights.bio/uploads/Clynes headshot copy.jpg" data-image="1"></div><div class="author-det"> <b>Raphael Clynes</b>, MD, PhD, Vice President of Translational Biology, Xencor. Dr. Clynes is a medical oncologist/hematolo-gist and a cellular immunologist with more than 100 publications in cancer and autoimmunity. Prior to joining Xencor in 2017, Dr. Clynes evaluated combination immunotherapies in Early Clinical Development at Bristol Myers Squibb. Prior to moving to industry in 2014, Dr. Clynes led NIH-funded research programs over two decades in cancer and autoimmunity at The Rockefeller University, MSKCC and Columbia University. </div></div></div>
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
